# Boryung Biopharma Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/boryung-biopharma-co

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.boryungbio.co.kr
- Total disclosed funding: $57M
- Latest round: Series B (Jun 1, 2020)
- Investors on record: 3

## About

Based in Seoul, South Korea, Boryung Biopharma specializes in the development and production of biopharmaceuticals, focusing on innovative therapies for oncology and autoimmune conditions.Founded in 1991, Boryung Biopharma Co., Ltd. is engaged in biopharmaceutical development, with its headquarters in Seoul, South Korea. The company recently underwent a significant shift, as Eugene Private Equity and Korea Development Bank acquired an 80% majority stake in the company for KRW 320 billion on July 27, 2024. Prior to this, Boryung Biopharma had been involved in a total of five deals. Founded by individuals whose details are not publicly available, the company has not reported any changes in its core business strategy or operations since its inception.Boryung Biopharma focuses on the development and production of biopharmaceuticals, particularly in the fields of oncology and autoimmune diseases. Their core product offerings include innovative therapeutic solutions designed to address complex medical needs, enhancing the quality of life for patients facing serious health challenges. The company's flagship products are aimed at both healthcare providers and patients requiring effective treatment options, with a strong emphasis on safety and efficacy. Boryung Biopharma primarily serves hospitals and clinics, with a growing presence in the Asian markets, particularly South Korea, Japan, and China. The products are tailored to meet the demands of diverse healthcare settings and are supported by ongoing research and development initiatives to expand their therapeutic portfolio.In 2023, Boryung Biopharma generated revenue of KRW 128,545,941.80 and reported an EBITDA of KRW 12,641,894.60. The company operates on a transactional model that includes direct sales to healthcare institutions and partnerships with distributors across various regions. Revenue generation is primarily from the sale of biopharmaceutical products, typically sold through agreements with hospitals and healthcare networks. This structure allows for flexible pricing arrangements tailored to the needs of large healthcare providers, ensuring effective delivery of its products to end-users in targeted geographical markets.Following the recent acquisition and investment, Boryung Biopharma is poised for growth through the expansion of its product line and market presence. The company plans to launch new products focused on addressing unmet medical needs in oncology and autoimmune treatment areas, with specific release dates pending further development. Additionally, Boryung Biopharma aims to enter new markets in Southeast Asia and expand its footprint in existing markets within Japan and China by the end of 2025. The funding from the recent Buyout round will support these initiatives, enhancing both product development and market entry strategies.

## Funding rounds

- Series B, Jun 1, 2020, $32M — Mirae Asset Securities, Tigris Investment
- Series A, Jul 26, 2018, $25M — Shinhan Capital

## Investors

- Shinhan Capital (https://capitalatlas.ai/funds/shinhan-capital) — Series A
- Mirae Asset Securities (https://capitalatlas.ai/funds/mirae-asset-securities) — Series B
- Tigris Investment (https://capitalatlas.ai/funds/tigris-investment) — Series B